A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. - Wikidata - awgldk - TriplyDB

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

http://www.wikidata.org/entity/Q39917871

about

Engineered IgG1-Fc--one fragment to bind them all Improving biophysical properties of a bispecific antibody scaffold to aid developability Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins Engineered clearing agents for the selective depletion of antigen-specific antibodies Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening Nanocell targeting using engineered bispecific antibodies.Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.Computationally Designed Bispecific Antibodies using Negative State Repertoires.Dual targeting strategies with bispecific antibodies.Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells.Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry.The making of bispecific antibodies T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.Redirecting Killer T Cells through Incorporation of Azido Sugars for Tethering Ligands.Controlled Fab-arm exchange for the generation of stable bispecific IgG1.Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

P2860

Q26766715-E1392DB5-BE75-4A16-9168-6D94C13B56E9 Q27679445-FA54B672-D5B0-42E2-A045-C6F377536644 Q28072319-7EC8F475-1537-4D15-8BF2-865C60819905 Q33766669-AEC9A6A7-1D95-4A0D-B17E-7F8DD8098FF4 Q34517676-CFAE1E0C-E420-4670-9FB8-C9CAFEAD630B Q34550963-969E5B18-DB74-4CC5-B6F3-24C2451634C9 Q35870955-70AB1FB8-CE19-4D8B-B021-166C1781A277 Q36211456-C4ADF33C-099C-4FC8-BD9C-E2B7229F2896 Q36729822-2F9E6FF5-0D6E-4294-B30A-BC6D5E9B0EB3 Q36899812-1068F769-6D58-4D0B-AF0C-DCC2EC6969D2 Q37997559-F123698C-E4AE-4E33-8F2B-4621F54A3225 Q38038410-10C96C99-EB4B-4814-A000-70F430E740FA Q38599353-D45BFBF0-E1DF-4521-87A8-A1F475C37BCA Q38790644-2F90D852-9886-4088-A94D-B5DA6F51EB6F Q38861238-EE7D70F0-426C-4046-B67D-E9CBD42788B8 Q40612349-7C68D2DE-D0B0-4DF7-93F2-B6EAD3228AE7 Q41647084-A29E9025-FC39-4F32-B88E-8A9A9DF737B9 Q41864920-0E7BA74F-5292-480F-8587-6A68ECE801F2 Q41899683-9F1190C9-02AA-4188-9197-84B51ABE1BA9 Q42323236-D042293A-B25D-452A-BE29-77FCDE3A9B93 Q47570404-35091908-B738-47C9-BAB9-3F44A60B1B45 Q47594827-9A0F37A9-140C-4E36-8579-81D8BF9409B6 Q47729518-69DE8D2D-4FB1-49CB-9A08-5F3245C558D2 Q48266324-46CAD917-8A3E-4425-AFA3-06D8AB01B8E3 Q50042227-BC841B51-92E4-4550-A71D-79BCA79292F5 Q50204340-56191AF8-55CB-43C5-B992-826BFD9035DB Q58724935-88A9BBDB-F64D-40D2-A629-C4A337755B2E

P2860

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

http://www.wikidata.org/entity/Q39917871

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

A novel bispecific antibody fo ...... t of distinct target antigens.

@en

A novel bispecific antibody fo ...... t of distinct target antigens.

@nl

type

label

A novel bispecific antibody fo ...... t of distinct target antigens.

@en

A novel bispecific antibody fo ...... t of distinct target antigens.

@nl

prefLabel

A novel bispecific antibody fo ...... t of distinct target antigens.

@en

A novel bispecific antibody fo ...... t of distinct target antigens.

@nl

P1433

Q39917871-17BD297E-FFD1-4B91-8B69-1256E10092B7

P1476

Q39917871-262AAF99-CA62-4D58-9E8F-027F9D3F6475

P2093

Q39917871-068402F4-B212-4458-AA63-CCDA4D8D0B72

Q39917871-0774A47B-4ADA-4B6F-9ADE-D627FF0111A3

Q39917871-34A00514-7A7A-46C8-BDDF-19DDC44F4A0E

Q39917871-57F068D0-A84B-420E-A5FD-976C3249FA60

Q39917871-98AAA93D-D82C-4F60-888B-7FA111CEB899

Q39917871-9D62A249-C70F-48C6-A9FD-C4B21CF17B7A

Q39917871-9E61FF70-2D9F-41E3-87D4-25DC62E243FC

Q39917871-B2AE97FA-3970-4AEC-BADD-6000D17A29B1

Q39917871-D651C265-8C29-49C9-ADFC-D6EAA1061942

Q39917871-DBC70D94-4153-451E-9D70-82E286091C40

P2860

Q39917871-01CF9C2E-8C2A-4ACB-9C21-BE39B5ED904A

Q39917871-0805E368-6E4F-4627-9A13-34DA2DC29081

Q39917871-0A22043F-E2CD-4A1F-A7A4-B0B9F3DDA772

Q39917871-0AAE2032-84BF-4A60-9D4B-A136C54B4B4F

Q39917871-0B50AD14-6E56-4125-85C0-5D72CA577086

Q39917871-1003E3B2-83E1-4234-9177-FD88A4E5D071

Q39917871-12849482-6ADD-4B47-B857-0E9D633BE232

Q39917871-19C88D9E-60F4-4EB2-AFA6-9D9A5BDDD077

Q39917871-1A6D9167-F2DC-4764-BC7B-0EC6350223DD

Q39917871-1DEBEC92-A6A4-40D7-9A11-B023C96F69D1

P304

Q39917871-F97D468F-6E53-4C8D-9B88-4D282FA42E16

P31

Q39917871-B0EAFDAE-9FEA-49BD-B2F3-AC40E4247DDB

P356

Q39917871-00E71377-5BEA-4535-BE90-8612397BD5E8

P433

Q39917871-3666DB60-F2B5-4F8C-8B22-DD81FCE17408

P478

Q39917871-7181C087-54EA-4617-A63F-993A226F9DF9

P577

Q39917871-BB60C04A-DE1E-42B6-A94A-BE4B0574179F

P5875

Q39917871-E93AAA50-BDE2-4C7E-9210-B261966FC7BE

P698

Q39917871-CDAD699E-4AA2-498D-A6AD-A96648DE98C6

P921

Q39917871-0C419FE8-B3D0-4F56-8C2B-B75322138B9C

P932

Q39917871-CFDDF5F0-45D5-4B71-B5AF-9EC9D7561C18

P356

P1433

Monoclonal Antibodies

P1476

A novel bispecific antibody fo ...... t of distinct target antigens.

@en

P2093

Araz Eivazi

http://www.w3.org/2001/XMLSchema#string

Cristina Bautista

http://www.w3.org/2001/XMLSchema#string

Duc-Hanh T Nguyen

http://www.w3.org/2001/XMLSchema#string

Erik Pong

http://www.w3.org/2001/XMLSchema#string

Greg A Lazar

http://www.w3.org/2001/XMLSchema#string

Gregory L Moore

http://www.w3.org/2001/XMLSchema#string

Jonathan Jacinto

http://www.w3.org/2001/XMLSchema#string

Seung Y Chu

http://www.w3.org/2001/XMLSchema#string

Sher Karki

http://www.w3.org/2001/XMLSchema#string

Umesh S Muchhal

http://www.w3.org/2001/XMLSchema#string

P2860

High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells

Humanization of an anti-p185HER2 antibody for human cancer therapy

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

Bispecific T-cell engaging antibodies for cancer therapy

Protein design automation.

A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.

Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.

Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome.

P304

546-557

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.3.6.18123

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51832335

http://www.w3.org/2001/XMLSchema#string

P698

22123055

http://www.w3.org/2001/XMLSchema#string

P921

P932

3242841

http://www.w3.org/2001/XMLSchema#string